Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H13Cl2NO4 |
| Molecular Weight | 354.1852 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc(c(c1)CC(=O)OCC(=O)O)Nc2c(cccc2Cl)Cl
InChI
InChIKey=MNIPYSSQXLZQLJ-UHFFFAOYSA-N
InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)
| Molecular Formula | C16H13Cl2NO4 |
| Molecular Weight | 354.1852 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) analog of Diclofenac. It is used for the relief of pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The dose is 100 mg twice daily, and should not be given to people with porphyria or breastfeeding mothers and is not recommended for children. Aceclofenac is a cytokine inhibitor. Aceclofenac works by blocking the action of a substance in the body called cyclo-oxygenase. Cyclo-oxygenase is involved in the production of prostaglandins (chemicals in the body which cause pain, swelling and inflammation). Aceclofenac is the glycolic acid ester of diclofenac. The incidence of gastric ulcerogenicity of aceclofenac has been reported to be significantly lower than that of other frequently prescribed NSAIDs: for instance, 2-fold less than naproxen, 4-fold less than diclofenac, and 7-fold less than indomethacin. Aceclofenac is metabolized in human hepatocytes and human microsomes to form [2-(2',6'-dichloro-4'-hydroxy- phenylamino)phenyl] acetoxyacetic acid as the major metabolite, which is then further conjugated.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL230 |
3.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Clanza CR Approved UseCLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date1.30515835E12 |
|||
| Palliative | Clanza CR Approved UseCLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date1.30515835E12 |
|||
| Palliative | Clanza CR Approved UseCLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date1.30515835E12 |
|||
| Palliative | Clanza CR Approved UseCLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date1.30515835E12 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. | 2001 Aug |
|
| Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. | 2001 Dec |
|
| [What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?]. | 2001 Jul |
|
| In-vitro test system for the evaluation of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibitors based on a single HPLC run with UV detection using bovine aortic coronary endothelial cells (BAECs). | 2001 May |
|
| [Toxic hepatitis caused by aceclofenac]. | 2001 Oct |
|
| Photoallergic contact dermatitis from aceclofenac. | 2001 Sep |
|
| Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. | 2002 |
|
| Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review. | 2002 Aug |
|
| Preparation and evaluation of aceclofenac microemulsion for transdermal delivery system. | 2002 Aug |
|
| Determination of aceclofenac in bulk and pharmaceutical formulations. | 2002 Jan 1 |
|
| Regulation by reactive oxygen species of interleukin-1beta, nitric oxide and prostaglandin E(2) production by human chondrocytes. | 2002 Jul |
|
| Stability-indicating spectrophotometric and densitometric methods for determination of aceclofenac. | 2002 May |
|
| [Acid coxibs, NO donors, cytokine inhibitors. New beginnings against rheumatism]. | 2002 Nov 28 |
|
| Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. | 2002 Oct 11 |
|
| [Exudative erythema multiforme with transition to a toxic epidermal necrolysis after taking aceclofenac (Beofenac)]. | 2003 Mar 7 |
|
| Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. | 2004 |
|
| Bioequivalence evaluation of two brands of aceclofenac 100 mg tablets (Aceclofar and Bristaflam) in healthy human volunteers. | 2004 Apr |
|
| Drug metabolism by cultured human hepatocytes: how far are we from the in vivo reality? | 2004 Jun |
|
| Pain and osteoarthritis: new drugs and mechanisms. | 2004 Sep |
|
| Polarographic behaviour of Aceclofenac, Tenoxicam and Droxicam in a methanol-water mixture. | 2004 Sep 21 |
|
| Comparative efficacy of aceclofenac and etoricoxib in post extraction pain control: randomized control trial. | 2005 Apr-Jun |
|
| Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. | 2005 Dec 1 |
|
| Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. | 2005 Nov 10 |
|
| Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. | 2005 Nov 29 |
|
| Formulation of microemulsion systems for transdermal delivery of aceclofenac. | 2005 Sep |
|
| Effect of processing variables on micro particulate system of aceclofenac. | 2006 Jan |
|
| Analgesic efficacy of aceclofenac after surgical extraction of impacted lower third molars. | 2006 Jun |
|
| Consumption costs of inappropriate medicines estimated from bulk purchase data: The example of NSAids in Guatemala. | 2006 Nov |
|
| Evaluation of bioequivalence of two formulations containing 100 milligrams of aceclofenac. | 2006 Nov-Dec |
|
| Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial. | 2007 Aug |
|
| Nanoemulsions as vehicles for transdermal delivery of aceclofenac. | 2007 Dec 14 |
|
| Preparation, in vitro, preclinical and clinical evaluations of once daily sustained release tablets of aceclofenac. | 2007 Feb |
|
| Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. | 2007 Jan |
|
| Improved bioavailability of aceclofenac from spherical agglomerates: development, in vitro and preclinical studies. | 2007 Jul |
|
| [After taking non-steroidal anti-inflammatory agents. What is the cause of the "blue spot?" ]. | 2007 Jul 19 |
|
| Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom. | 2007 Jun |
|
| Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. | 2007 Mar |
|
| Photodegradation and in vitro phototoxicity of aceclofenac. | 2007 May |
|
| Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction? | 2007 May |
|
| Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. | 2008 Apr |
|
| Cyclooxygenase inhibitors induce apoptosis in sinonasal cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene. | 2008 Apr 15 |
|
| Simultaneous determination of aceclofenac, paracetamol, and chlorzoxazone by RP-HPLC in pharmaceutical dosage form. | 2008 Aug |
|
| Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. | 2008 Dec |
|
| Simultaneous determination of aceclofenac and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. | 2008 Feb 13 |
|
| Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan-based solvent change approach. | 2008 Feb 28 |
|
| Two cases of acute leukopenia induced by colchicine with concurrent immunosuppressants use in Behçet's disease. | 2008 Feb 29 |
|
| Mathematical evaluation of similarity factor using various weighing approaches on aceclofenac marketed formulations by model-independent method. | 2008 Jan |
|
| Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. | 2008 Jul 9 |
|
| Preventing peridural fibrosis with nonsteroidal anti-inflammatory drugs. | 2008 Mar |
|
| Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. | 2008 Oct |
Patents
Sample Use Guides
In vitro adhesion assays were developed to examine the effects of aceclofenac on both neutrophil adhesion to tumor necrosis factor alpha stimulated human umbilical vein endothelial cells under nonstatic conditions, and homotypic neutrophil aggregation induced by anti-ICAM-3 and anti-CD18 monoclonal antibodies (Mab)
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:15:41 UTC 2021
by
admin
on
Fri Jun 25 21:15:41 UTC 2021
|
| Record UNII |
RPK779R03H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QM02AA25
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
||
|
WHO-ATC |
M02AA25
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
||
|
WHO-VATC |
QM01AB16
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
||
|
WHO-ATC |
M01AB16
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C80534
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | |||
|
M1293
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | Merck Index | ||
|
RPK779R03H
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | |||
|
71771
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | |||
|
16689
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | RxNorm | ||
|
43
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | |||
|
ACECLOFENAC
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | |||
|
5608
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | |||
|
CHEMBL93645
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | |||
|
89796-99-6
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | |||
|
SUB05200MIG
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | |||
|
89796-99-6
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | |||
|
C056498
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY | |||
|
DB06736
Created by
admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
